Smith & Nephew Executives Reinvest 2025 Final Dividend into Company Shares
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
An update from Smith & Nephew Snats ( (SNN) ) is now available.
Smith & Nephew plc reported that several senior executives acquired ordinary shares under its Dividend Re-Investment Plan following the 2025 final dividend payment on 27 May 2026. The purchases, made on the London Stock Exchange, involved ordinary shares of USD 0.20 each and were disclosed in line with UK Market Abuse Regulation requirements.
Chief executive officer Deepak Nath, chief financial officer John Rogers and other senior managers, including the heads of global operations, compliance and sports medicine, all participated in the reinvestment plan. The move modestly increases insider ownership and provides investors with additional transparency into leadership alignment with shareholders ahead of future capital allocation decisions.
The most recent analyst rating on (SNN) stock is a Hold
with a $30.00 price target.
To see the full list of analyst forecasts on Smith & Nephew Snats stock,
see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock,
click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company that develops and manufactures orthopaedic implants, sports medicine products and advanced wound care solutions for global healthcare markets. The group focuses on surgical and patient care innovations aimed at improving clinical outcomes and serving hospitals, clinics and specialist treatment centres worldwide.
Average Trading Volume: 1,055,301
Technical Sentiment Signal: Hold
Current Market Cap: $12.47B
See more data about SNN stock on TipRanks’ Stock Analysis page.
